Eli Lilly Buys AtaiBeckley to Expand Depression Pipeline
Eli Lilly is acquiring AtaiBeckley in a $2.8 billion cash deal, with up to $1 billion in additional contingent value rights (CVRs). The acquisition adds BPL-003, which holds FDA Breakthrough designation for treatment-resistant depression (TRD), to Lilly's pipeline. The deal is expected to close in Q3 2026.
DeFi Intel is an entity-graph aggregator: we curate, tag and link crypto news to a typed knowledge graph of protocols, tokens, people and incidents. We do not republish the full article body. Use the link above to read the original report at Cryptodaily.
Entities in this story
Discussion
Comments are reviewed before publication.
Want the full article?
Continue reading on Cryptodaily →
No comments yet.